54.63 0.00 (0.00%)
After hours: 4:31PM EDT
|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||54.52 - 54.91|
|52 Week Range||37.38 - 55.43|
|PE Ratio (TTM)||76.51|
|Dividend & Yield||1.06 (1.94%)|
|1y Target Est||N/A|
The market is upbeat about Integra LifeSciences' (IART) latest developments that include product launches and strategic buyouts.
In 3Q17, the Established Pharmaceuticals segment of Abbott Laboratories is expected to report high double-digit operational sales growth.
The 3Q17 EPS estimate for Abbott Laboratories is $0.65. The company has provided an EPS guidance range of $0.64–$0.66 for 3Q17.
Analysts expect Abbott Laboratories to report 3Q17 revenues of ~$6.7 billion, representing a YoY (year-over-year) growth of ~26.7%.
DENTSPLY SIRONA's (XRAY) renewed distribution deal will aid the company to gain market traction. However, forex woes remain a concern.
On October 18, 2017, Abbott Laboratories will release its 3Q17 earnings results. Abbott stock was trading at its 52-week high of $55.4 on October 10.
The market is upbeat about QIAGEN's (QGEN) partnership and co-marketing agreement with CENTOGENE AG to boost its bioinformatics portfolio.
Abbott's (ABT) FreeStyle Libre system receives back-to-back reimbursement approvals in several geographies, which are likely to drive growth in the Diabetes Care sales segment within Medical group.
The move comes as Germany's Merck KGaA (MRCG.DE) is also looking to divest its non-prescription products, including brands such as Seven Seas vitamins, which could be worth around $4.5 billion. As ageing populations and health-conscious consumers drive demand for self-medication, the fragmented consumer health sector has proved a fertile ground for deal-making in recent years. Pfizer's consumer healthcare business, whose brands include painkiller Advil and lip balm Chapstick, had revenue of about $3.4 billion in 2016.
QIAGEN (QGEN) makes another encouraging move to expand its advanced bioinformatics portfolio and add additional capabilities, partners CENTOGENE.
Illumina rides high on product launches, including the latest release of VeriSeq NIPT in Europe, and strong uptake of NovaSeq. Weak margins remain a concern.
DexCom, Inc. (NASDAQ: DXCM ) shares got hammered Sept. 28 when rival Abbott Laboratories (NYSE: ABT ) received FDA approval for its FreeStyle Libre flash glucose monitoring system. Investors see Abbott’s ...
This could indicate that investors who seek to profit from falling equity prices are not currently targeting ABT. Over the last one-month, outflows of investor capital in ETFs holding ABT totaled $5.89 billion.
Rating Action: Moody's to withdraw Alere's ratings following debt redemption. Global Credit Research- 05 Oct 2017. New York, October 05, 2017-- Moody's Investors Service will withdraw Alere Inc.' s ratings ...
A pacemaker for the brain can be used to treat symptoms of neurological disorders like Parkinson’s Disease.
Abbott (ABT) announced the FDA approval of its Freestyle Libre on September 27, and some analysts have updated their recommendations.
On August 30, ABT announced the regulatory approval for its dydrogesterone oral medication in Russia and the Netherlands for invitro fertilization treatment.